Processus Kft.

The research facility Processus Kft. in Budapest concentrates on psychiatry and psychology, targeting major depressive disorder. Ongoing studies evaluate innovative adjunctive and monotherapy approaches to lessen depressive symptoms, with special attention to patients experiencing moderate‑to‑severe anhedonia or anxious distress.

• Adjunctive aticaprant for MDD with moderate‑to‑severe anhedonia
• Safety and tolerability of oral SPT‑300 in MDD
• Monotherapy assessment of SPT‑300 in MDD with or without anxious distress

The site is currently running three clinical trials under the guidance of two investigators, generating essential data on new treatment options for patients who have not achieved sufficient response to standard antidepressants.